Dec. 27 (Bloomberg) -- Seattle Seahawks starting cornerback Richard Sherman said he won his appeal of a four-game suspension for violating the National Football League’s performance-enhancing drug policy.
Sherman, who along with teammate Brandon Browner tested positive for an undisclosed substance, appealed last month based on errors in the chain of custody of his sample and because of mistakes made by the tester, ESPN said. News of the initial ban was reported Nov. 26 and the substance in question was the prescription drug Adderall, a stimulant used to treat attention-deficit hyperactivity disorder, or ADHD, ESPN said.
“Thank you @nfl for upholding the truth! To the 12s Thank you, your faith is rewarded! Thank you lord,” Sherman said today in a Twitter post, referencing his appreciation of Seattle’s fans, known as the “12th man.”
A second post said: “I won.”
George Atallah, a spokesman for the NFL Players Association, confirmed the ruling to USA Today. An e-mail seeking comment from Atallah wasn’t immediately returned.
The NFL’s drug agreement with its players’ union includes a confidentiality agreement that precludes all parties, including the players, from discussing test results publicly.
“We are reviewing the decision, but decline comment at this time due to the confidentiality provision of the program,” Greg Aiello, a spokesman for the NFL, said in an e-mail.
Dave Pearson, a spokesman for the Seahawks, said in an e-mail that the team would defer to the league.
The 24-year-old Sherman has seven interceptions this season for the Seahawks, who are 10-5 and have clinched a playoff berth. He had an interception and returned a blocked field-goal try 90 yards for a score on Dec. 23 as Seahawks beat the San Francisco 49ers 42-13.
Browner, 28, began his suspension Dec. 5, and will miss the Seahawks’ final four regular-season games, including the Dec. 30 finale against the St. Louis Rams. Seattle won all three of its games in his absence.
To contact the reporter on this story: Mason Levinson in New York at email@example.com
To contact the editor responsible for this story: Michael Sillup at firstname.lastname@example.org